Abstract: Major depressive disorder (MDD) is one of the most prevalent conditions in psychiatry. Patients who do not respond to traditional monoaminergic antidepressant treatments have an especially difficult-to-treat type of MDD termed treatment-resistant depression. Subanesthetic doses of ketamine-a glutamatergic modulator-have shown great promise for rapidly treating patients with the most severe forms of depression. As such, ketamine represents a promising probe for understanding the pathophysiology of depression and treatment response. Through neuroimaging, ketamine's mechanism may be elucidated in humans. Here, we review 47 articles of ketamine's effects as revealed by neuroimaging studies. Some important brain areas emerge, especially the subgenual anterior cingulate cortex. Furthermore, ketamine may decrease the ability to self-monitor, may increase emotional blunting, and may increase activity in reward processing. Further studies are needed, however, to elucidate ketamine's mechanism of antidepressant action.
M ajor depressive disorder (MDD) is devastating, serious, and prevalent. Treatment-resistant depression (TRD)-often defined as failure to respond to at least two standard antidepressant treatment trials of adequate dose and duration-encompasses up to 30% of patients with MDD. 1 Not only is TRD highly debilitating for patients and their families, the economic strain from TRD accounts for nearly $200 billion a year from lost productivity. The more treatment failures that patients experience, the less likely they are to respond to subsequent treatment trialsperpetuating the cycle of disability. For these reasons, it is critical to find fast and effective treatments for patients with TRD.
One compound that holds promise for TRD is ketamine. While commonly considered a dissociative anesthetic, subanesthetic doses of ketamine stand out among other pharmacological interventions for MDD. While most commonly used psychiatric medications (e.g., selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors) require multiple weeks to take full effect, subanesthetic doses of ketamine have rapid (within hours), robust (across a variety of symptoms), and relatively sustained (typically up to one week) antidepressant effects-even in patients with TRD. [2] [3] [4] [5] Clinical studies show that about 50% of patients with TRD have a significant decrease in symptoms within 24 hours of a single intravenous subanesthetic ketamine dose. 5 Animal models show that ketamine's antidepressant effects are likely mediated by its antagonism of N-methyl-D-aspartate (NMDA) receptors through increased α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-mediated glutamatergic signaling. This triggers activation of intracellular synaptogenic pathways, most notably in the mechanistic target of rapamycin (mTOR)-signaling pathway, which also has implications in many other psychiatric disorders. 1, 6 In fact, ketamine was first used to probe the glutamatergic system as it relates to the pathophysiology of schizophrenia. The original neuroimaging studies on ketamine's mechanism were thus used as working models for schizophrenia because excess glutamate has been linked to the development of schizophrenia and psychosis. 7 With regard to MDD patients, decreased glutamate has been noted in various prefrontal regions, including the dorsolateral prefrontal cortex (dlPFC), dorsomedial PFC (dmPFC), and anterior cingulate cortex (ACC), when compared to controls. [8] [9] [10] This shortage of glutamate makes ketamine an ideal treatment for MDD; by creating a surge in glutamate levels in regions of the brain that suffer from a glutamate deficit, ketamine may provide some normalization of glutamate levels in patients with MDD. This "glutamate surge" hypothesis has dominated as the primary theory of ketamine's antidepressant mechanism.
The glutamate surge hypothesis, however, has met with some controversy. In a review of neuroimaging studies specifically examining how ketamine modulates glutamate and gamma-aminobutryic acid (GABA), it was unclear whether glutamate levels, which surged during infusion, remained elevated postinfusion. 11 One study found increased glutamate levels in the ACC 35 minutes postinfusion, but another found no change. 12, 13 Multiple studies attempted to find a correlation between antidepressant response and glutamate/GABA levels before, during, and after infusion, [14] [15] [16] but no correlations were found.
It is possible, then, that ketamine is acting indirectly to produce its antidepressant effect. Ketamine may work through additional receptors, as it is known to have effects on several opioid receptors, adrenergic receptors, and several serotonin and norepinephrine transporters. [17] [18] [19] It is also possible that acute dissociative side effects of ketamine may be mediating antidepressant response. In turn, it is equally possible that small sample sizes among studies utilizing ketamine prevent results from converging. Methodological differences and limitations may also play a role. Due to inconsistent results and ketamine's heterogeneity of action, it is hard to elucidate the mechanism by which ketamine produces its rapid, robust, and sustained antidepressant effects. Therefore, further research on ketamine's antidepressant mechanism is needed, and theories on biological and clinical responses need to be explored.
One salient biological metric that may provide insight into ketamine's mechanism of action is related to dissociation. Dissociative side effects begin from infusion, reach a peak typically within an hour of infusion, and are completely diminished 230 minutes after infusion. 20 The same study has shown that increased dissociation and psychotomimetic symptoms immediately following infusion may predict antidepressant response. 20 Further neuroimaging research has the potential not just to inform scientists of ketamine's antidepressant mechanism but to inform clinicians as to who might best respond to ketamine as an antidepressant. Other biological metrics include baseline brain activity, psychotomimetic effects during infusion, and anxiety somatization levels.
The advent of advanced imaging techniques allows noninvasive investigations of neuronal activity in patients with TRD and in healthy controls. These imaging results can then be correlated not just with glutamate and GABA levels but with clinical and biological metrics that could provide insight into how ketamine produces its antidepressant effect.
-Positron emission tomography (PET) and magnetic resonance spectroscopy (MRS) provide the most direct noninvasive methods for measuring glutamatergic and GABA-ergic activity. They acquire full volumes of the brain at various time points during and after ketamine infusion. -Magnetoencephalogram (MEG) recordings measure small magnetic and electric changes in the brain through sensors placed at the scalp. While MEG is a more indirect measure of GABA and glutamate, it assesses brain function of all regions on a time scale that better reflects real-time neural activity. Functional magnetic resonance imaging (fMRI) and resting-state fMRI provide less temporal resolution than MEG (full brain volumes are only acquired every~3 seconds), but they provide more precise measurements of subcortical regions of the brain. This is important for studying regions such as the subgenual ACC and amygdala, which are commonly targeted in MDD. 21 MEG and fMRI also allow investigators to study how brain function changes as subjects undergo in-scanner tasks, such as passive viewing of faces and decision making. Task-based fMRI and MEG can provide more ecologically valid information about what the brain does when faced with real-life situations. They can also tell us more about how the brain's real-life performance is altered in patients with MDD.
-Diffusion MRI and structural MRI enable tracking of how ketamine may change the brain's anatomy and how structural connections change over time. This is of interest because rapidly induced synaptogenesis has been shown in preclinical models in response to ketamine. 6 Thus, here we review current human neuroimaging literature as it pertains to ketamine's mechanism of action in specific brain areas, with an emphasis on key regions that are implicated in the pathophysiology of MDD. We focus this review on treatment studies of patients with MDD. However, because very little literature specifically examines ketamine's actions in patients with MDD, we are including research with healthy volunteers. Research in healthy volunteers may enable us to understand how ketamine affects neural organization and activity without psychopathology. We end by summarizing the results as they pertain to the neurobiology of depression and ketamine's antidepressant effects. By understanding the biological basis of disease pathology and treatment response, the field of psychiatry has the potential to practice more precise medicine-ultimately with improvements in both patient care and outcomes.
METHODS
A Medline search was conducted for articles through December 2016 using the following search terms: depression and ketamine and neuroimaging; depression and ketamine and imaging; depression and ketamine and MRI; ketamine and neuroimaging; ketamine and imaging. All articles reviewed were written and published in English, and pertained to adult human research only. A total of 966 were initially found. After duplicate articles and nonhuman research articles were removed, 47 were found to be relevant to this review. We segment the results into three sections: (1) Ketamine and Neuroimaging in Depression, (2) Ketamine in Nondepressed Subjects: Non-task-based Resting-State Scans, and (3) Ketamine in Nondepressed Subjects: Task-Based Scans. Though most studies examined only one modality of imaging, several 7,9,10 employed more than one.
RESULTS

Ketamine and Neuroimaging in Depression
Thirteen studies were found to be relevant to ketamine's effects in patients with unipolar depression, and two in patients with bipolar depression. See Table 1 . Among unipolar depression studies, several groups utilized fMRI. With regard to brain connectivity, one study found that in patients with TRD, ketamine increased neural responses to positive emotions in the right caudate; furthermore, greater connectivity in the right caudate post-ketamine was associated with improvements in depression severity. 31 In another study, Abdallah and colleagues 32 found that patients with MDD had reduced global brain connectivity (the average of the correlation between the blood oxygen level-dependent (BOLD) time series of a voxel and all other gray matter voxels in the brain) in the prefrontal cortex (PFC) compared to healthy volunteers at baseline, but increased global brain connectivity in the posterior cingulate, precuneus, lingual gyrus, and cerebellum. Ketamine significantly increased global brain connectivity in the right lateral PFC and reduced global brain connectivity in the left cerebellum. Furthermore, ketamine responders had increased connectivity in the lateral PFC, caudate, and insula compared to nonresponders. Downey and colleagues 33 recently found that ketamine increased BOLD signals in the subgenual ACC. Activation of the subgenual ACC predicted depression improvements at 24 hours and one week post-ketamine; the results are difficult to interpret, however, because in this study ketamine did not induce the pre-specified decrease in activity in the region-of-interest within the subgenual ACC and did not show any antidepressant effect superior to placebo.
With regard to structural MRI results, Abdallah and colleagues 28 found a significant association between smaller left hippocampal volumes at baseline and greater antidepressant responses to ketamine at 24 hours postinfusion in patients with depression. A diffusion MRI study found that at baseline, increased fractional anisotropy (a measure of connectivity strength in the principal axis of the structural connection) in the cingulum projecting the PFC, decreased mean diffusivity (a measure of membrane density) and radial diffusivity (a measure of myelination) in the forceps minor, and decreased radical diffusivity in the frontostriatal tract were associated with ketamine response, defined as 50% improvement in depression symptoms at 24 hours.
35 Table 1 Continued Most patients (n = 9) were not medication free; they were maintained on stable (≥6 months) standard antidepressant treatments MRI was not done at a standardized time point
Small n ACC, anterior cingulate cortex, BOLD, blood oxygen level-dependent; GABA, gamma-aminobutyric acid; GBCr, global brain connectivity signal regression; Glx, glutamate+glutamine; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; MEG, magnetoencephalography; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; MTG, middle temporal gyrus; OFC, orbitofrontal cortex; PET, positron emission tomography; PFC, prefontal cortex; rCMRGlu, regional cerebral metabolic rate of glucose; STG, superior temporal gyrus.
Ketamine-Associated Brain Changes
Other studies that utilized MEG provide more information about the role of the ACC. Salvadore and colleagues 22 found that increased baseline cortical activity to fearful pictures in the ACC-especially the pregenual ACC-and decreased baseline amygdala activation each predicted a greater antidepressant response to ketamine at four hours postinfusion. Another study from the same group examined baseline predictors of ketamine response during a working-memory task. Patients who had the least pre-ketamine engagement of the pregenual ACC with increasing memory load showed the greatest antidepressant improvement to ketamine at four hours postinfusion. 23 In addition, those with the lowest coherence between pregenual ACC and left amygdala were most likely to respond to ketamine. Since we would expect healthy controls to have high pregenual ACC activity in response to emotional stimuli and low pregenual ACC activity in response to increased cognitive demands, these data suggest that normal baseline activity in the pregenual ACC predicts better antidepressant outcomes to ketamine.
In another MEG study, Nugent and colleagues 34 found decreased connectivity between the amygdala and insulotemporal regions post-ketamine. Based on the theory by Duman and colleagues 36,37 that ketamine's antidepressant effects result from rapid increases in synaptic plasticity, Cornwell and colleagues 24 designed a tactile-stimulation task as a mean of indirectly gauging synaptic plasticity in the somatosensory cortex via MEG acquisition recorded 6.5 hours post-ketamine. Compared to nonresponders, responders at four hours postinfusion had increased somatosensory cortical excitability (a measure of synaptic plasticity).
Several studies explored ketamine's effects on whole-brain metabolism using PET. Lally and colleagues 30 at the National Institute of Mental Health (NIMH) found that decreased anhedonia post-ketamine was associated with increased metabolism in the hippocampus and the dorsal ACC, and decreased metabolism in the orbitofrontal cortex (OFC). Another study from the same NIMH group found that decreased suicidal ideation scores post-ketamine correlated with decreased metabolism in the infralimbic cortex. 29 Furthermore, Carlson and colleagues 25 administered PET scans at 120 minutes postketamine and compared them to baseline scans. Decreased metabolism in the right habenula, right insula, right ventrolateral PFC, and dorsolateral PFC was found post-ketamine. Furthermore, clinical improvements significantly correlated with increased metabolism in the superior temporal gyrus, middle temporal gyrus, and cerebellum, and with decreased metabolism in the parahippocampal gyrus and inferior parietal cortex.
Two studies focused on bipolar depression using PET. Lally and Nugent 34 used PET scans at 120 minutes postketamine to measure metabolism in patients with bipolar depression; note, all patients in these studies were maintained on stable doses of either lithium or valproic acid. Specifically, Lally and colleagues 26 found that decreased anhedonia correlated with increased metabolism in the dorsal ACC and putamen. Nugent and colleagues 34 found that patients who received ketamine had significantly lower glucose metabolism in the left hippocampus compared to those who received placebo; furthermore, patients with the largest improvement in depression symptoms had the largest metabolic increase in the right ventral striatum post-ketamine compared to placebo. In addition, metabolism of the subgenual ACC positively correlated with improvements in depression scores following ketamine.
Ketamine in Nondepressed Subjects: Non-task-based Resting-State Scans Twenty-one resting-state scan studies were found relevant to this review-mostly using MRI and MRS (see Tables 2 and 3) . From MRI studies, some highlights emerged. Several studies examined how ketamine affected cerebral blood flow (CBF). Two studies showed that ketamine reduced CBF in the hippocampus and increased CBF in the ACC and prefrontal regions. 38, 41 Other studies found that ketamine reduced CBF in the OFC and subgenual ACC. 40, 49 In one particular study, this reduction strongly predicted dissociation (r = 0.90 with the Clinician Administered Dissociative States Scale scores). 40 In another study, perceptual distortions and delusion ratings following ketamine correlated with increased BOLD response in the parietal cortex. 49 With regard to resting-state fMRI, one study found that ketamine decreased connectivity in the auditory and somatosensory networks in relation to regions of physical and affective processing of pain (e.g., amygdala, insula, and ACC). 41 In another study, ketamine reduced functional connectivity between the pregenual ACC and dorsal posterior cingulate cortex (dorsal PCC); this reduction in connectivity correlated significantly with increased psychotomimetic effects during the infusion. 56 Ketamine decreased functional network connectivity in healthy subjects; specifically, ketamine disrupted connectivity between the pregenual ACC, medial PFC, and the bilateral dmPFC 24 hours after infusion. 43 One study examined the effects of ketamine on brain connectivity with increasing levels of sedation (awake, mildly sedated, heavily sedated). Increased levels of sedation correlated significantly with decreased connectivity in the medial PFC with the default mode network and also between the left and right executive-control networks. Thalamo-cortical connectivity remained relatively preserved. 50 Ketamine also had significant effects on hippocampal connectivity. One resting-state fMRI study found that ketamine induced hyperconnectivity in hippocampal networks vulnerable to mood and cognitive disorders. 41 Moreover, another study observed that hyperconnectivity between the PFC and the left hippocampus occurred after acute ketamine challenge. 47 MRS techniques have also implicated ketamine's role in brain connectivity and hippocampal function. Ketamine induced an increase in hippocampal Glx (glutamate + glutaminean indication of enhanced excitatory neurotransmission) and a decrease in frontotemporal and temporoparietal functional connectivity in a combined MRS/fMRI study. 52 This suggests a possible link between connectivity changes and elevated Glxnamely, that NMDA receptor hypofunction may lead to elevated hippocampal glutamatergic transmission and alterations in the resting-state network. This finding was supported by a study in which ketamine was found to decrease NMDA-and AMPA-mediated frontoparietal connectivity. 48 One study imaged participants using fMRI during both a ketamine infusion and placebo infusion. 51 The authors found that, compared to placebo, BOLD activation increased during the ketamine condition in the bilateral middle cingulate cortex, ACC, and insula, as well as in the right thalamus.
Finally, with regard to MEG, one study found increased gamma power during the infusion, while beta band activity was decreased. 58 This effect was noted in the thalamus, hippocampus, and frontocortical regions. Connectivity, as measured by transfer entropy (how much information is transferred from a source to a target process), increased within the thalamocortical network. This study's results highlight a potential contribution of the thalamocortical pathways in ketamine's initial neuronal dysregulation.
Ketamine in Nondepressed Subjects: Task-Based Scans Fifteen task-based scan studies were found, 14 of which used fMRI (see Tables 3 and 4) .
Several studies examined ketamine's effects during and after emotion tasks. In one study, ketamine attenuated taskinduced activation in the amygdalo-hippocampal complex; specifically, reductions in BOLD activation were more marked in response to negative pictures than to neutral or positive pictures. 57 Furthermore, increased intensity of the acute psychedelic side effects on consciousness during ketamine exposure predicted the reduction in neuronal responsiveness to negative (but not neutral or positive) pictures. The authors suggested that perhaps the emotional blunting ("attenuated limbic hyperactivity") during dissociation plays a role in the alleviation of negative bias in people with depression (though no patients with depression were actually included in the study).
During a different emotion-pictures task, increased BOLD activation was observed 24 hours post-ketamine infusion in the pregenual ACC (but not the posterior control regions) during the negative picture-viewing blocks. 56 The increase in BOLD activation was more pronounced, however, in subjects with a low ability to apply distraction during the negative experiences. In another emotion task, ketamine significantly reduced BOLD activation in the right insula regardless of task's emotional valence; in the left insula and right dlPFC, BOLD activation was reduced only in response to negative stimuli. 69 Compared to placebo (in which several brain areas [amygdala, visual-processing areas, and cerebellum] significantly activated during a fearful-faces task), the ketamine group significantly activated only the left superior occipital gyrus. 54, 55 These data are somewhat related to another study in which ketamine led to impaired selfmonitoring, which was related to reduced activation in the left superior temporal cortex. Together, these data suggest that the NMDA receptor may be involved in producing the impaired self-monitoring that occurs during hallucinatory or delusional experiences. 65 Several studies examined ketamine's effects on working memory. In one study, ketamine increased activation in frontoparietal regions (dlPFC, bilateral ventrolateral areas, bilateral parietal cortices, ACC, putamen, and caudate nucleus) compared to placebo during the task phase of manipulation of verbal information (at the easiest point). 59 In another study, ketamine increased activation of the left PFC to deeply encoded items during an episodic-memory task. 60 Specifically, correctly identified items during ketamine were associated with increased activation of the right PFC during encoding compared to incorrectly identified items. Items incorrectly identified at retrieval were associated with increased activation of the right PFC and hippocampus under ketamine but not placebo. By contrast, in one study, ketamine impaired working-memory performance. 66 Ketamine reduced taskrelated activation in the PFC during a spatial task, especially during the encoding and early-maintenance phases. Ketamine also reduced connectivity during the task in the network brain areas involved in working memory. Reductions in activation and connectivity were related to performance.
Finally, one study found that ketamine induced a general impairment of verbal fluency. 64 During the phonic verbalfluency task, several brain regions (left temporal gyrus, superior frontal gyrus to middle frontal gyrus, medial frontal gyrus, and left inferior parietal lobe) were more activated by ketamine than in other conditions. During the lexical verbal-fluency task, the right frontal and left supramarginal regions were activated significantly more with ketamine.
DISCUSSION
Although the neuroimaging literature on ketamine's effects is in its early stages, certain themes have emerged. First are our findings of convergent brain regions implicated in MDD and how ketamine modulates those areas. Specifically, the subgenual ACC has been a region of interest in many previous studies. In relation to emotion and cognition, ketamine appears to reduce brain activation in regions associated with self-monitoring, to increase neural regions associated with emotional blunting, and to increase neural activity in reward processing.
Overall, ketamine's effects were most notably found in the subgenual ACC, PCC, PFC, and hippocampus. Abnormalities in overlapping regions (specifically, the dorsal and subgenual ACC, amygdala, hippocampus, and ventral striatum) have been implicated, via a growing body of neuroimaging literature, in the pathophysiology of depression. [70] [71] [72] [73] [74] The subgenual ACC, in particular, has been a frequently studied area of interest concerning ketamine and MDD. In healthy male volunteers, resting-state fMRI and pharmacological MRI done during ketamine infusion found significant reductions in subgenual ACC coupling with hippocampus, retrosplenial cortex, and thalamus. Immediate reductions Table 3 Studies with Both Resting-State Scans and Task Scans (Nondepressed Populations) in the amygdalo-hippocampal complex during the emotion task; specifically, reductions in BOLD reactivity was more marked in response to negative pictures compared to neutral or positive pictures, suggesting that the processing of negative information is specifically altered in response to ketamine 57 Also, reduced amygdala activity to negative pictures was correlated with resting-state connectivity to the pregenual ACC Increased intensity of psychedelic side effects of consciousness during ketamine predicted the reduction in neuronal responsiveness to negative (but not neutral or positive) pictures ACC, anterior cingulate cortex; BOLD, blood oxygen level-dependent; fMRI, functional magnetic resonance imaging; IAPS, International Affective Picture System; rsfMRI, resting state functional magnetic resonance imaging. 40, 53 Some other imaging studies of the subgenual ACC, however, seem to provide contradictory results. NIMH studies using PET 120 minutes postinfusion found that increased metabolism in the subgenual ACC was positively correlated with improvements in depression scores post-ketamine. 27 A different PET study in MDD, however, found no change in subgenual ACC metabolism post-ketamine. 25 In addition to indicating that larger, more controlled studies are needed, these inconsistent results suggest that the timing of the scan may matter. Changes in subgenual ACC activation may be related to ketamine's acute side effects, which begin during infusion, reach a peak typically within an hour of infusion, and are completely absent 230 minutes after infusion. Against this background, it is possible that subgenual ACC activation decreases during and immediately after ketamine infusion, but changes again a few hours later, returning to normal.
Analysis of resting-state scans in healthy volunteers further suggests that dissociation may be responsible for ketamine's antidepressant effects because it may disconnect the "excessive effects of an aversive visceromotor state on cognition and the self"-a hallmark of depression.
40(p 163) Related, one study found that ketamine may dampen brain regions involved in rumination (the repetitive focusing of attention on negative feelings and thoughts in response to negative mood) by reducing the functional connectivity between the pregenual ACC and the dorsal PCC, and decreasing connectivity between the left and right executive-control networks. 56 In fact, ketamine has been shown to interfere with the default mode network (a system involved in internal and external sensory processing) 75 by disrupting the "hyperconnectivity"-commonly associated with rumination-between it and the medial PFC in patients with MDD. 50, 57 One ongoing study (ClinicalTrials.gov ID: NCT02544607) aims to further investigate default mode network changes and hyperconnectivity in patients with TRD before and after a ketamine infusion. Taken together, these studies suggest that ketamine may cause a "disconnect" in several circuits related to affective processing, perhaps by shifting focus of attention away from the internal states of anxiety, depression, and somatization, and more toward the perceptual changes (e.g., hallucinations, visual distortions, derealization) induced by ketamine. Similarly, during an emotion task, ketamine attenuated responses to negative pictures, suggesting that the processing of negative information is specifically altered in response to ketamine. 57 By taking the focus off "oneself" and placing it on other stimuli, it is possible that ketamine decreases awareness of negative experiences and consequently improves mood.
Perhaps most interesting are ketamine's effects on brain connectivity as it relates to self-monitoring behaviors. Reduced connectivity between the pregenual ACC and dorsal PCC was associated with increased dissociation during infusion, and reduced activation in the left superior temporal cortex was associated with impaired self-monitoring 56, 65 -which is disruptive to patients with psychotic illness-especially those with chronic symptoms of psychosis. By contrast, the transient dissociation experienced by depressed patients during a ketamine infusion may have the effect of dampening what the hyperactive self-monitoring associated with depressive illness.
During ketamine administration, subjects experience emotional blunting, which may be associated with reduced limbic responses to emotional stimuli. 54, 55 It is possible that by decreasing the activity of deep limbic structures (thought to be involved in the pathophysiology of depression, such as the amygdala), ketamine acutely disables the emotional resources required to perpetuate the symptoms of depression.
Ketamine may play a role in reactivating reward areas of the brain in patients with MDD. This reactivation may be especially important, as reward areas in MDD have been characterized by decreased subcortical and limbic activity and by an increased cortical response to reward paradigms. 76 In resting-state scans, BOLD activation in the cingulate gyrus, hippocampus, insula, thalamus, and midbrain increased after ketamine. 49 In addition, ketamine increases neural activation in the bilateral MCC, ACC, and insula, as well as the right thalamus. 51 Activation of these areas is consistent with activation of reward-processing areas, suggesting that ketamine may play a role in activating reward neurocircuitry. 76 Though no single brain area has been singled out as the locus of depression, ketamine affects different areas of the brain in various ways, which may contribute to overall mood improvements. For example, at baseline, patients with MDD, compared to healthy volunteers, had reduced global connectivity in the PFC and increased connectivity in the posterior cingulate, precuneus, lingual gyrus, and cerebellum; postketamine, responders had increased connectivity in the lateral PFC, caudate, and insula. 32 These findings may reflect ketamine's ability to reclaim frontal control over deeper limbic structures, thus strengthening the cognitive control of emotions and decreasing depressive symptoms. Similarly, TRD patients, compared to healthy volunteers, had reduced insula and caudate responses to positive emotions at baseline, which normalized in the caudate post-ketamine. 31 Furthermore, while one study showed increased connectivity in the lateral PFC, caudate, and insula in ketamine responders, another found decreased connectivity between the amygdala and insulo-temporal regions. 32, 34 Improvements are correlated with increased metabolism in the hippocampus, dorsal ACC, and decreased metabolism in the OFC. 30 Yet another group found that improvements correlated with increased metabolism in the superior/middle temporal gyrus and cerebellum, and decreased metabolism in the parahippocampal gyrus and inferior parietal cortex. 25 Further investigation of these seemingly sporadic results may provide further insight into ketamine's antidepressant effects.
Several limitations in this review warrant discussion. First, it is hard to extrapolate information about ketamine's antidepressant properties from the existent literature, because the majority of published studies are from healthy volunteers. Second, most of the task-based healthy volunteer studies used male volunteers only, which may limit generalizability. Third, most of the studies completed have very few participants; even the depression study with the most participants had only 24 subjects. Given the immense heterogeneity of depression, further studies with larger sample sizes will be necessary in order to capture the full range of patients with depression. Fourth, it is still difficult to temporally parse out which findings occur due to ketamine's antidepressant mechanism alone versus which changes are due to the appearance of psychotropic side effects immediately post-ketamine. This may be especially relevant to ketamine imaging studies because of the timing of its side effects (1-2 hours) versus antidepressant effect (hours to days) in relation to the timing of the imaging procedure. Fifth, although most studies used racemic ketamine, several others used the S-ketamine enantiomer. This difference may be important because S-ketamine may have greater affinity to the NMDA receptor than the R-ketamine enantiomer. 77 Finally, it is important to note that most depression studies use subanesthetic ketamine doses of 0.5 mg/kg over 40 minutes because this dose effectively treats depression. Many studies with nondepressed patients, however, used alternative doses. Though a study for ketamine's optimal antidepressant dose was recently completed (ClinicalTrials.gov ID: NCT01920555), the results are pending. Nonetheless, these reasons make it difficult to generalize the results of this review to large patient populations with depression.
Further research is necessary to uncover ketamine's antidepressant mechanism of action and address the above limitations. Such research may help to uncover new working models of the biological substrates of depression and enable new drug discovery. Specifically, based on this review, future studies should likely focus on ketamine's action in the subgenual ACC, PCC, PFC, and hippocampus. Another promising direction for research builds on the view that depression is the product of underactive prefrontal and limbic mood-regulation networks and overreactive subcortical limbic networks, which are involved in emotional and visceral responses. 78 Perhaps these network abnormalities in depression-and their improvement with treatment-can be further elucidated through the use of ketamine. Indeed, ketamine's remarkable rapid, robust, and sustained antidepressant effects are considered to be "arguably the most important discovery in half a century" for depression research.
37(p 68) Ketamine's potential use in both research and treatment is promising indeed.
